Income Statement

Download CSV
Year Ending Dec 2025 (Update) Year Ending Dec 2024 (Update) Year Ending Dec 2023 (Update) Year Ending Dec 2022 (Update)
Net Sales 1.23
Revenue 1.23
Total Revenue 1.23 0.00 0.00 0.00
Cost of Revenue 0.51
Cost of Revenue, Total 0.51
Gross Profit 0.72
Selling/General/Administrative Expense 12.92 13.12 13.64 27.31
Labor & Related Expense 0.14 0.39 0.57
Selling/General/Administrative Expenses, Total 13.06 13.51 14.22 27.31
Research & Development 3.78 6.20 13.37 17.03
Depreciation 0.07
Depreciation/Amortization 0.07
Other Unusual Expense (Income) 6.24 0.93 0.25 0.00
Unusual Expense (Income) 6.24 0.93 0.25 0.00
Other, Net 0.00
Other Operating Expenses, Total 0.00
Total Operating Expense 23.65 20.63 27.84 44.34
Operating Income -22.43 -20.63 -27.84 -44.34
Interest Expense - Non-Operating -0.67 -0.23 -0.12 0.00
Interest Expense, Net Non-Operating -0.67 -0.23 -0.12 0.00
Interest Income, Non-Operating 0.01 0.04 0.49 0.25
Investment Income, Non-Operating -0.04 0.26
Interest/Investment Income, Non-Operating -0.02 0.04 0.49 0.50
Interest Income (Expense), Net-Non-Operating, Total -0.69 -0.19 0.37 0.50
Other Non-Operating Income (Expense) -5.50 -4.31 -2.69 4.08
Other, Net -5.50 -4.31 -2.69 4.08
Net Income Before Taxes -28.62 -25.13 -30.15 -39.75
Income Tax – Total 0.00 0.00 0.00
Income After Tax -28.62 -25.13 -30.15 -39.75
Net Income Before Extraordinary Items -28.62 -25.13 -30.15 -39.75
Net Income -28.62 -25.13 -30.15 -39.75
Miscellaneous Earnings Adjustment 0.00 -0.01 0.00
Total Adjustments to Net Income 0.00 -0.01 0.00
Income Available to Common Excluding Extraordinary Items -28.62 -25.13 -30.16 -39.75
Income Available to Common Stocks Including Extraordinary Items -28.62 -25.13 -30.16 -39.75
Basic Weighted Average Shares 21.40 10.64 7.58 6.58
Basic EPS Excluding Extraordinary Items -1.34 -2.36 -3.98 -6.04
Basic EPS Including Extraordinary Items -1.34 -2.36 -3.98 -6.04
Diluted Net Income -28.62 -25.13 -30.16 -39.75
Diluted Weighted Average Shares 21.40 10.64 7.58 6.58
Diluted EPS Excluding Extraordinary Items -1.34 -2.36 -3.98 -6.04
Diluted EPS Including Extraordinary Items -1.34 -2.36 -3.98 -6.04
DPS - Common Stock Primary Issue
Gross Dividends - Common Stock 0.00 0.00 0.00 0.00
Total Special Items 6.24 0.93 0.25 0.00
Normalized Income Before Taxes -22.39 -24.20 -29.90 -39.75
Effect of Special Items on Income Taxes 0.00 0.00 0.00 0.00
Income Taxes Excluding Impact of Special Items 0.00 0.00 0.00 0.00
Normalized Income After Taxes -22.39 -24.20 -29.90 -39.75
Normalized Income Available to Common -22.39 -24.20 -29.91 -39.75
Basic Normalized EPS -1.05 -2.27 -3.95 -6.04
Diluted Normalized EPS -1.05 -2.27 -3.95 -6.04
Amortization of Intangibles, Supplemental 0.09
Depreciation, Supplemental 0.01 0.01 0.01 0.00
Interest Expense, Supplemental 0.67 0.23 0.12 0.00
Rental Expense, Supplemental 0.11 0.10 0.10 0.10
Stock-Based Compensation, Supplemental 0.18 0.49 0.39 3.63
Equity in Affiliates, Supplemental -0.04
Research & Development Expense, Supplemental 3.78 6.20 13.37 17.03
Audit-Related Fees, Supplemental 0.32 0.47 0.74 0.78
Audit-Related Fees 0.00
Tax Fees, Supplemental 0.00
All Other Fees Paid to Auditor, Supplemental 0.00
Gross Margin 58.78
Operating Margin -1,830.61
Pretax Margin -2,336.49
Effective Tax Rate
Net Profit Margin -2,336.49
Normalized EBIT -16.19 -19.70 -27.59 -44.34
Normalized EBITDA -16.09 -19.70 -27.58 -44.33
Current Tax - Domestic
Current Tax - Local
Current Tax - Total
Deferred Tax - Domestic -1.33 -4.72
Deferred Tax - Local -0.23 -0.04
Deferred Tax - Total -1.56 -4.76
Local Tax - Other
Other Tax 1.56 4.76
Income Tax - Total 0.00 0.00

In millions of USD (except for per share items)

Source: LSEG

Corporate Presentation

Click here to view our corporate presentation or on the image below
Corporate Presentation
IP Portfolio
View Our Pipeline
Contact NRx Pharmaceuticals